Evidence map›Paper›PMID 26559139›Full record

Trial reportBMC neurology2015

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Michael G Dwyer, Robert Zivadinov, Yazhong Tao, Xin Zhang, Cheryl Kennedy, Niels Bergsland, Deepa P Ramasamy, Jackie Durfee, David Hojnacki, Bianca Weinstock-Guttman and 3 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01085318 (A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01085318 phase4completednot on this map

A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group

TypeinterventionalSponsorEMD SeronoRan2010 to 2012Enrolled38ConditionsMultiple SclerosisArmsRebif
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Interferon β for Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Michael G DwyerDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. mgdwyer@bnac.net.
Robert ZivadinovDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. rzivadinov@bnac.net.
Yazhong TaoDepartment of Neurology, Microbiology and Immunology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC, 27599, USA. yztao@med.unc.edu.
Xin ZhangDepartment of Neurology, Microbiology and Immunology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC, 27599, USA. zhangx@neurology.unc.edu.
Cheryl KennedyDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. ckennedy@bnac.net.
Niels BergslandDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. npbergsland@bnac.net.
Deepa P RamasamyDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. dramasamy@bnac.net.
Jackie DurfeeDepartment of Neurology, Buffalo Neuroimaging Analysis Center, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. jdurfee@bnac.net.
David HojnackiDepartment of Neurology, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. hojnacki@buffalo.edu.
Bianca Weinstock-GuttmanDepartment of Neurology, State University of New York at Buffalo, 100 High St, Buffalo, NY, 14203, USA. bweinstock-guttman@kaleidahealth.org.
Brooke HaywardEMD Serono, Inc., One Technology Pl, Rockland, MA, 02370, USA. brooke.hayward@emdserono.com.
Fernando DangondEMD Serono, Inc., One Technology Pl, Rockland, MA, 02370, USA. fernando.dangond@emdserono.com.
Silva Markovic-PleseDepartment of Neurology, Microbiology and Immunology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC, 27599, USA. markovics@neurology.unc.edu.
University at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · USOno Pharmaceutical (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain volume atrophy is observed in relapsing-remitting multiple sclerosis (RRMS).

methodsBrain volume changes were evaluated in 23 patients with RRMS treated with interferon β-1a 44 μg given subcutaneously (SC) three times a week (tiw) and 15 healthy controls. Percentages of whole brain and tissue-specific volume change were measured from baseline (0 months) to 3 months, from 3 to 6 months, and from baseline to 6 months using SIENAX Multi Time Point (SX-MTP) algorithms. Immunological status of patients was also determined and correlations between subsets of T cells and changes in brain volume were assessed.

resultsInterferon β-1a 44 μg SC tiw in 23 patients with RRMS resulted in significant reductions in whole brain and gray matter tissue volume early in the treatment course (baseline to 3 months; mean change; -0.95%; P = 0.030, -1.52%; P = 0.004, respectively), suggesting a short-term treatment-induced pseudoatrophy effect. From baseline to 6 months, there were significant correlations observed between decreased T- cell expression of IL-17 F and decreased whole brain and brain tissue-specific volume.

conclusionsThese findings are consistent with the interpretation of the pseudoatrophy effect as resolution of inflammation following treatment initiation with interferon β-1a 44 μg SC tiw, rather than disease-related tissue loss.

trial registrationClinicalTrials.gov; NCT01085318.

Indexed as

AdultAgedAlgorithmsAtrophyBrainFemaleHumansInflammationInjections, SubcutaneousInterferon-betaInterferon beta-1aInterleukin-17MaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingOrgan SizeIL17F protein, humanInterferon-betaInterferon beta-1aInterleukin-17

Identifiers

PMID26559139
PMCPMC4642690
OpenAlexW2177319653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.